Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer

Conditions:   HER2-positive Breast Cancer;   ER-positive Breast CancerInterventions:   Drug: fulvestrant 500 mg;   Drug: Docetaxel (T) 75 mg/m2 (Taxotere);   Drug: Trastuzumab (H, 8mg/kg;   Drug: Pertuzumab (P, 840 mgSponsor:   Western Regional Medical CenterRecruiting - verified January 2015
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials